1 / 11

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer. Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH For Questions contact: Beat Müller , happymiller@bigfoot.com Martin A. Walter , m.a.walter@gmx.net. Medullary Thyroid Cancer.

serge
Download Presentation

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 177Lu-Dota-NOCate&177Lu-Dota-Gastrinin Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH For Questions contact: Beat Müller, happymiller@bigfoot.com Martin A. Walter, m.a.walter@gmx.net

  2. Medullary Thyroid Cancer Treatment Options: • Surgery (first line) • To date no effective systemic treatment option • Radiation Therapy is not well defined • Treatment options with different Radiopeptides are currently evaluated

  3. Aim To assess the value of 177Lu-Dota-NOCate and 177Lu-Dota-Gastrin in Imaging and Treatment of Metastatic Medullary Thyroid Cancer Ethically Approved (EKBB)

  4. Signal 177Lu Target Somatostatin/ CCK2-Receptor Ligand Somatostatin/ Gastrin-Analogs Radiopeptides

  5. Metastases Tumor Application Distribution Accumulation „Magic Bullet“ Approach

  6. Affinity Profile (Dota-NOC-ATE)

  7. Receptor Profile (MTC) EB Forssell-Aronsson. J Nucl Med2000;41:636–642

  8. Pilot-Patient (Dota-NOC-ATE) Specific Tumor Uptake (LN-metastesis) p9581 ♂, 63y Metastised MTC

  9. Patients Patients with progressive MTC Exclusion criteria: • Karnofsky Performance Status < 50% • Refusion of a 1-year contraception • Pregnancy • Breast-feeding • Age<18

  10. Diagnostic Scintigraphy • Scintigraphy + Dosimetry (first compound, outpatient, 2d) • Scintigraphy + Dosimetry (second compound, outpatient, 2d) 2 weeks later • Significant Accumulation + Favorable Biodistribution → Treatment

  11. Treatment • Inpatient • 3 Days • Day 1: Injection of Radiopeptide + Amino Acid Infusion (Kidney Protection) • Day 2: Imaging • Day 3: Release of Patient

More Related